117 related articles for article (PubMed ID: 23959947)
1. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF
Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947
[TBL] [Abstract][Full Text] [Related]
2. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Liang KH; Lin CC; Yeh CT
Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146
[TBL] [Abstract][Full Text] [Related]
3. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma.
Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT
Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683
[TBL] [Abstract][Full Text] [Related]
4. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy.
Lin CC; Hsu CW; Chen YC; Chang ML; Liang KH; Lai MW; Lin CL; Chien RN; Lin KH; Yeh CT
Pharmacogenomics J; 2020 Feb; 20(1):57-68. PubMed ID: 31611591
[TBL] [Abstract][Full Text] [Related]
5. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization.
Liang KH; Lin CL; Chen SF; Chiu CW; Yang PC; Chang ML; Lin CC; Sung KF; Yeh C; Hung CF; Chien RN; Yeh CT
Pharmacogenomics; 2016 Mar; 17(4):353-66. PubMed ID: 26871639
[TBL] [Abstract][Full Text] [Related]
6. Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Lin CL; Chien RN; Yeh C; Hsu CW; Chang ML; Chen YC; Yeh CT
Scand J Gastroenterol; 2014 Dec; 49(12):1456-64. PubMed ID: 25283499
[TBL] [Abstract][Full Text] [Related]
7. Retrospective comparison between a regular and a split-dose protocol of 5-fluorouracil, cisplatin, and mitoxantrone for the treatment of far advanced hepatocellular carcinoma.
Yeh CT; Chen HC; Sung CM; Hsu CL; Lin CC; Pan KT; Tseng JH; Hung CF
BMC Cancer; 2011 Mar; 11():117. PubMed ID: 21453495
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Yang TS; Chang HK; Chen JS; Lin YC; Liau CT; Chang WC
J Gastroenterol; 2004; 39(4):362-9. PubMed ID: 15168248
[TBL] [Abstract][Full Text] [Related]
9. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.
Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT
Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048
[TBL] [Abstract][Full Text] [Related]
10. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.
Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT
Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726
[TBL] [Abstract][Full Text] [Related]
11. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
Chen WT; Lin SM; Lee WC; Wu TJ; Lin CC; Shen CH; Chang ML; Lin CL; Yeh CT
Hepatol Int; 2022 Feb; 16(1):148-158. PubMed ID: 34982369
[TBL] [Abstract][Full Text] [Related]
12. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251
[TBL] [Abstract][Full Text] [Related]
13.
Lin WR; Hsu CW; Chen YC; Chang ML; Liang KH; Huang YH; Yeh CT
Mol Clin Oncol; 2014 Jul; 2(4):630-640. PubMed ID: 24940508
[TBL] [Abstract][Full Text] [Related]
14. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells.
Chu YD; Fan TC; Lai MW; Yeh CT
Cell Death Dis; 2022 Nov; 13(11):956. PubMed ID: 36376274
[TBL] [Abstract][Full Text] [Related]
15. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Ikeda M; Okusaka T; Ueno H; Takezako Y; Morizane C
Cancer; 2005 Feb; 103(4):756-62. PubMed ID: 15637692
[TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
18. [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Naganuma A; Toyoda M; Hamada T; Hagiwara S; Yanagisawa M; Kosone T; Arai H; Abe T; Takagi H
Gan To Kagaku Ryoho; 2007 May; 34(5):729-34. PubMed ID: 17496446
[TBL] [Abstract][Full Text] [Related]
19. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
[TBL] [Abstract][Full Text] [Related]
20. [Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
Masutani S; Shimizu J; Tatsuta M; Masuda F; Imamura H; Ishida H; Furukawa H; Tomotsu K; Yura M; Obana T; Kitamura S; Saeki N; Inoue Y; Takamura M; Ohnishi H
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1579-82. PubMed ID: 14619468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
